Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 12/19/2014 7:37:28 AM - Followers: 161 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 12/12/2014 04:33:01 PM
CVM News: CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites 12/08/2014 08:45:00 AM
CVM News: CEL-SCI Quarterly Patient Enrollment in Its Head & Neck Cancer Phase III Trial Increases Eight Fold over Same Prior Year Period 12/02/2014 08:30:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/07/2014 02:58:41 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/05/2014 09:27:10 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6496   Then hopefully, the Inventiv case will be settled Foxwoods Man 12/19/14 07:37:28 AM
#6495   Here is the timing of the last notification majatamata 12/18/14 09:32:55 PM
#6494   CVM is burning $6m per qtr. They most peterose 12/18/14 05:21:47 PM
#6493   And - I don't think they'll do another Foxwoods Man 12/18/14 01:21:43 PM
#6492   I don't think we see a 'pop' up drkazmd65 12/18/14 11:33:00 AM
#6491   It matters not that we may have another r/s. Foxwoods Man 12/18/14 08:10:01 AM
#6490   Just say multikine has shown great results for peterose 12/17/14 09:49:31 PM
#6489   NVGN popped $4 yesterday. All the CEO said peterose 12/17/14 09:46:03 PM
#6488   It matters not that we may have another Turney 12/17/14 09:25:31 PM
#6487   What would tge revers split be 1 share peterose 12/17/14 07:38:04 PM
#6486   Unfortunately... there will be another r/s Badmulez 12/17/14 04:04:09 PM
#6485   I would guarantee that the Annual report is Foxwoods Man 12/17/14 02:42:57 PM
#6484   Hopefully, there is no bad news to report peterose 12/17/14 02:30:17 PM
#6483   And since we're all retail, the summary is... PlanTrader 12/17/14 08:06:42 AM
#6482   I know what you are trying to do, learning curve 12/16/14 10:37:15 PM
#6481   Last quarter the end of august report $29 peterose 12/15/14 12:21:53 PM
#6480   I was trying to differentiate between ESTABLISHING a Foxwoods Man 12/15/14 07:44:56 AM
#6479   Still missing the point. If I hold 10m learning curve 12/14/14 11:18:34 PM
#6478   Geert is very deceptive. This time last peterose 12/13/14 01:08:06 PM
#6477   There last quarterly report says they have enough Foxwoods Man 12/13/14 12:56:54 PM
#6476   You can file for fda fast track approval peterose 12/13/14 11:44:08 AM
#6475   There last quarterly report says they have enough peterose 12/13/14 11:40:20 AM
#6474   Notification That Annual Report Will Be Submitted Late Foxwoods Man 12/12/14 04:46:24 PM
#6473   It will all work out in the end Badmulez 12/12/14 06:14:27 AM
#6472   The last shareholder letter was sent on 12/12/13. Foxwoods Man 12/11/14 02:57:15 PM
#6471   I definately tend to agree with your assessment drkazmd65 12/10/14 03:25:36 PM
#6470   I like your point of view but I Foxwoods Man 12/10/14 12:22:31 PM
#6469   I take this as a positive news overall Thinking-Longterm 12/10/14 12:08:22 PM
#6468   This is the LAST mention of anything regarding Foxwoods Man 12/10/14 07:26:27 AM
#6467   Hmmm...maybe we weren't the only ones in the dark: Foxwoods Man 12/10/14 07:09:06 AM
#6466   Yes I am very upset and intend to kurious 12/09/14 06:19:05 PM
#6465   So....no one is upset (except for a couple) Foxwoods Man 12/09/14 05:49:25 PM
#6464   Now we know why the decision by the peterose 12/09/14 11:40:23 AM
#6463   Glad I have resisted temptation because I woulda Badmulez 12/09/14 10:45:02 AM
#6462   Thanks for the heads up on that article. Foxwoods Man 12/09/14 07:45:38 AM
#6461   Thanks for posting the link. This is serious. peterose 12/08/14 10:06:18 PM
#6460   http://www.outsourcing-pharma.com/Clinical-Development/Enrollment-in-study-incre majatamata 12/08/14 09:24:30 PM
#6459   Article in cbsmarketwatch under cvm. Inventiv and Cel-Sci peterose 12/08/14 07:11:35 PM
#6458   The only pop this stock will get is peterose 12/08/14 12:41:40 PM
#6457   Is it possible to receive regulatory approval to peterose 12/08/14 12:20:26 PM
#6456   Agreed majatamata - but by doing things like drkazmd65 12/08/14 10:12:27 AM
#6455   CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head drkazmd65 12/08/14 10:09:48 AM
#6454   I hope this does something today. At least majatamata 12/08/14 09:28:04 AM
#6453   This is a great example of my failure learning curve 12/08/14 02:08:33 AM
#6452   Lol. peterose 12/07/14 09:27:05 PM
#6451   Your prediction has more of a chance of Foxwoods Man 12/07/14 10:12:36 AM
#6450   You're correct about institutions but hedge funds can peterose 12/07/14 09:19:41 AM
#6449   In this case I believe it represents a Foxwoods Man 12/07/14 08:26:01 AM
#6448   I understand that. You put a great explanation learning curve 12/07/14 12:40:35 AM
#6447   The flu vaccine this year does not protect Turney 12/05/14 10:00:21 AM
PostSubject